Skip to main content

briquilimab

briquilimab: developed by 1 company · 4 clinical trials tracked.

briquilimab evidence translation

What we can confirm

What it means

Source-backed records connect briquilimab to JSPR; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could briquilimab → JSPR affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Chronic Inducible Urticaria; Chronic Spontaneous Urticaria; Urticaria ChronicChronic Inducible UrticariaChronic Spontaneous Urticaria

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Jasper Therapeutics Inc. (JSPR)
Chronic Inducible Urticaria; Chronic Spontaneous Urticaria; …
Phase 1
Clinical Trials (4)

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

NCT06592768·Phase 1·JSPR
Terminated

Primary endpoint: To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants

InterventionalRandomizedquadruple17 enrolledStarted 2024-11Completion 2025-086 sites · CanadaJasper Therapeutics, Inc.

Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria

NCT06736262·Phase 2·JSPR
Terminated

Primary endpoint: To evaluate the safety and tolerability of briquilimab

Interventionalopen67 enrolledStarted 2024-11Completion 2026-0719 sites · Germany, United StatesJasper Therapeutics, Inc.

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT06353971·Phase 1/Phase 2·JSPR
Terminated

Primary endpoint: Incidence and severity of treatment emergent AEs/SAEs [safety and tolerability] of a single dose of briquilimab in patients with ColdU or SD who remain symptomatic despite the use of H1 antihistamines.

Interventionalopen27 enrolledStarted 2024-03Completion 2025-075 sites · GermanyJasper Therapeutics, Inc.

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines and/or Omalizumab, or Who Cannot Tolerate Omalizumab

NCT06162728·Phase 1/Phase 2·JSPR
Completed

Primary endpoint: Evaluate the safety and tolerability of briquilimab

InterventionalRandomizedquadruple87 enrolledStarted 2023-11Completion 2026-0723 sites · Germany, United StatesJasper Therapeutics, Inc.

Frequently asked questions

Who is developing briquilimab?

briquilimab is being developed by Jasper Therapeutics Inc..

How many clinical trials involve briquilimab?

BioSniper tracks 4 clinical trials involving briquilimab.